COVID-19-associated liver injury is defined as any liver damage that occured during during the course of infection and treatment of COVID-19 patients, with or without preexisting liver disease. This includes a broad spectrum of potential pathomechanisms, including direct cytotoxicity from active viral replication of SARS-CoV-2 in the liver and immune-mediated liver damage due to the severe inflammatory response/ systemic inflammatory response syndrome (SIRS) in COVID-19. Data was taken from 206 patients with COVID-19 who were admitted to our hospital and were examined physically. Laboratory and ultrasound results showed abnormal rates associated with liver disease. The four-year study was conducted from January 2018 to December 2021. 116 pts were collected in the period 2018 to 2019 (2 years precov) and 90 pts 2 years (2020-2021) in the era of the COVID-19 pandemic. Women’s precov was 60 pts and dcov was 30 pts, while men showed 56 pts and 60 pts precov during COVID-19 infection. Liver cirrhosis was 28 pts precov and 41 pts dcov, followed by NSRH 25 pts precov and 12 pts dcov, NASH 24 pts precov and 6 pts dcov, Hep. B 20 precov and 10 dcov, acute viral hepatitis 12 precov and 16 dcov points. In total liver cirrhosis placed the first rank 69 pts (33, 5%). Followed by NSRH 17, 96 %; NASH 14, 56%, B. Hep. 14, 56 % and Ac.viral Hep. 13, 59%. Keywords: pre-during pandemic covid-19, liver disease, liver cirrhosis